Business Wire

LFB Announces the Approval of CEVENFACTA® (eptacog beta) in the European Union

25.7.2022 17:35:00 EEST | Business Wire | Press release

Share

LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

  • in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU));
  • in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX.

Denis Delval, LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the approval of CEVENFACTA ® by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union. This approval is a validation of our innovative LFB technology and the acknowledgement of LFB’s deep commitment to patients.”

Dr. Patrick Delavault, MD, LFB’s Executive Vice President Scientific, Medical and Regulatory Affairs, stated: “We need to keep in mind constantly what a bleeding event, even a single bleeding event, means to a haemophilia patient with inhibitors and to his family. This novel treatment alternative is a significative opportunity to improve patients’ lives”.

LFB has been granted a Marketing Authorisation for SEVENFACT® (eptacog beta) in Mexico on June 2nd for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors.

About PERSEPT studies:

The approval of CEVENFACTA® was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3.

The PERSEPT 1 Phase III, multicentre, randomised, open-label crossover study of two initial dose regimens (75µg/kg and 225µg/kg), evaluated 468 bleeding episodes across the full type of severity of bleeding episodes (mild, moderate, and severe), in 27 adolescent and adult haemophilia A and B patients with inhibitors (12-54 years of age). Both dosing regimens met the primary endpoint with 81% and 90% of bleeds controlled at 12 hours with the 75µg/kg dose and the 225µg/kg dose respectively. By 24 hours, haemostatic efficacy (secondary endpoint) was retained in 96.7% of bleeding episodes treated with the 75 µg/kg dose regimen and 99.5% of redundancy bleeding episodes treated with the 225 µg/kg dose, without requiring any alternative therapy. The median time to attain haemostatic efficacy was 5.98 hours for the 75 µg/kg dosing regimen and 3 hours for the 225 µg/kg dosing regimen. A median of 2 injections was needed to treat a bleeding episode with the 75 µg/kg and a median of only 1 injection of the 225 µg/kg dosing regimen was needed.

The PERSEPT 3 Phase III, multicentre, open-label, single-arm study evaluated the safety and efficacy of CEVENFACTA® in haemophilia A or B patients with inhibitors who were scheduled for an elective surgical or other invasive procedure. 12 patients were enrolled in the study, 6 with minor procedures and 6 with major procedures. For major surgical/invasive procedures, treatment was administered at an initial bolus dose of 200 µg/kg immediately before the start of the invasive procedure. For a minor elective surgical procedure, an initial bolus dose of 75 µg/kg was administered immediately before the start of the procedure. Overall, 81.8% of procedures were reported as successfully treated at 48 hours after the last administration of the product.

No thromboembolic events were reported in these two clinical trials. No Serious Adverse Events (SAEs) were considered as related to the treatment.

Patients should be monitored for any signs of thrombosis, hypersensitivity and neutralising antibodies. The most frequently reported adverse reactions in studies were infusion site discomfort, infusion site haematoma, post-procedural haematoma, infusion related reaction, increased body temperature, dizziness and headache.

About LFB

LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care.

LFB currently markets 15 biomedicinal products in more than 30 countries.

Please visit www.groupe-lfb.com for further information on LFB.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LFB Contact:
Didier Véron - Executive Vice President, Corporate Affairs
Tel: +33 (0)1.69.82.72.97 or +33 (0)6.08.56.76.54
verondidier@lfb.fr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 17:05:00 EET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 16:00:00 EET | Press release

ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer at ViTAA Medical said: “The SVS deserves credit for its foresight in embracing advances in AI, digital healt

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 15:39:00 EET | Press release

Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population

Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 15:30:00 EET | Press release

Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specification that lets any payment provider add Klarna to AI agent checkout. “Agentic

SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 12:05:00 EET | Press release

SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing on a rolling basis through December 2026. It takes SatSure’s total capital raised to INR 427 crore (c. USD 46 millio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye